Use of ribaxamase (SYN-004), a β-lactamase, to prevent Clostridium difficile infection in β-lactam-treated patients: a double-blind, phase 2b, randomised placebo-controlled trial
- Resource Type
- Article
- Source
- In
The Lancet Infectious Diseases May 2019 19(5):487-496 - Subject
Primary Research Articles - Language
- ISSN
- 1473-3099